Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Details

ClinicalTrials.gov ID: NCT03833154
Diagnosis Type: NSCLC
USOR Number: 19044

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Sherman

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

  • Details

ClinicalTrials.gov ID: NCT02954991
Diagnosis Type: NSCLC
USOR Number: 17039

  • Practice Details

2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - McKinney

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

5236 W University Dr, Suite 1000
McKinney, Texas 75071
272.69 mi. away
P: (972) 542-8609

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - McKinney

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

5236 W University Dr, Suite 1000
McKinney, Texas 75071
272.69 mi. away
P: (972) 542-8609

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Wichita Falls

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

5400 Kell West Blvd
Wichita Falls, Texas 76310
274.39 mi. away
P: (940) 691-8271

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Wichita Falls

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

5400 Kell West Blvd
Wichita Falls, Texas 76310
274.39 mi. away
P: (940) 691-8271

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Denton

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3720 South I-35 East
Denton, Texas 76210
281.47 mi. away
P: (940) 382-1022

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Denton

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

3720 South I-35 East
Denton, Texas 76210
281.47 mi. away
P: (940) 382-1022

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Denton

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

3720 South I-35 East
Denton, Texas 76210
281.47 mi. away
P: (940) 382-1022

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Plano

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Plano

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Plano

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

4708 Alliance Blvd, Suite 150
Plano, Texas 75093
287.97 mi. away
P: (972) 596-7801

More Details View Practice Page

Pages